Status:
COMPLETED
Effect of Addition of Mannitol to Bupivacaine on IANB Success and Post-endodontic Pain
Lead Sponsor:
Cairo University
Conditions:
Irreversible Pulpitis
Eligibility:
All Genders
17-35 years
Phase:
PHASE2
PHASE3
Brief Summary
Inferior alveolar nerve block using either 0.5% bupivacaine alone or in addittion to mannitol in patients with irreversible pulpitis in mandibular molars.
Detailed Description
Patients with irreversible pulpitis in mandibular molars will be selected according to the eligibility criteria and patients are then randomized to either using 0.5% bupivacaine alone or in addition t...
Eligibility Criteria
Inclusion
- Adult patients; age between 17-35 years old.
- Males or Females.
- Medically-free patients
- Patients suffering from symptomatic irreversible pulpitis without apical periodontitis in mandibular molar teeth.
- Positive patients' acceptance for participation in the study.
Exclusion
- Patients who had any analgesic during proceeding 12 hours before the treatment.
- Teeth with necrotic, infected pulp, swelling or symptomatic apical periodontitis (apical abscess).
- Pregnant females.
- Patients with history of significant medical conditions (contraindication of mannitol use).
- Addiction
- Psycological disturbance.
Key Trial Info
Start Date :
December 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03749408
Start Date
December 1 2012
End Date
June 1 2014
Last Update
November 23 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.